SETD7-mediated lysine monomethylation is abundant on non-hyperphosphorylated nuclear Tau
Maria Bichmann, Nuria Prat Oriol, Ebru Ercan-HerbstiD, David C. SchöndorfiD, Borja Gomez RamosiD, Vera Schwärzler, Marie Neu, Annabelle SchlüteriD, Xue Bing WangiD, Liang JiniD, Chenqi HuiD, Yu TianiD, Janina S. Ried, Per HaberkantiD, Laura GaspariniiD, Dagmar E. EhrnhoeferiD
Abstract
Human tauopathies including Alzheimers disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, leading to the formation of insoluble aggregates, neuronal dysfunction and degeneration. Using a mass spectrometry approach, we identified multiple sites of lysine monomethylation on Tau isolated from a detergent-soluble fraction of human brain, some of which were increased in early AD samples. Brain tissues derived from a mouse model of tauopathy demonstrate an age-dependent increase in methylation at specific sites, with methylated Tau enriched in the soluble nuclear fraction and not associated with hyperphosphorylated, insoluble Tau species. Furthermore, we show that the protein lysine methyltransferase SETD7 methylates Tau at K132 and demonstrate an interaction with K130, an additional methylation site in close vicinity. These findings shed light on the function of a novel type of PTM on Tau that provide a potential signal for its translocation to different subcellular sites. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may furthermore provide insight into this disease-associated phenomenon.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 31
- FWCI
- 2.67
- Field percentile
- top 10%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer’s disease brain
Ebru Ercan-Herbst, Jens Ehrig, … Dagmar E. Ehrnhoefer·Acta Neuropathologica CommunicationsPeer-reviewed·Dec 1, 2019
- Stage-dependent tau post-translational modifications map the spatiotemporal progression of Alzheimer's disease
Axelle Vanparys, Clémence Balty, … Bernard Jimmy Hanseeuw·bioRxiv·Apr 10, 2026
- Post-translational modifications in the brain are critical contributors to Alzheimers disease neuropathology and cognitive decline
Julia B. Libby, Emily R. Mahoney, … Timothy J. Hohman·Alzheimer s & DementiaPeer-reviewed·Dec 1, 2025
- Combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications
Friedel Drepper, Jacek Biernat, … Eckhard Mandelkow�·Journal of Biological ChemistryPeer-reviewed·Oct 26, 2020
- Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau
N. Ait-Bouziad, A. Chiki, … H. Lashuel·bioRxiv·Jan 6, 2020
- Tau phosphorylated at serine 356 is associated with Alzheimer's disease pathology and can be lowered in mouse and human brain tissue using the NUAK inhibitor WZ4003
Lewis W. Taylor, Elizabeth M. Simzer, … Claire S. Durrant·Acta NeuropathologicaPeer-reviewed·Jan 4, 2024